CA-DC-CONNECTED-CAR
DC Connected Car GmbH, a trailblazer in AI-driven remote vehicle diagnostics, announces the closure of a €2.1M seed funding round. Led by Insurtech-fund VENPACE, this round includes contributions from Borusan Ventures, Atlas Ventures, Network.VC, and existing investors APX, Bloomhaus Ventures, and Business Angels. This investment accelerates DC Connected Car's mission to revolutionize the $500B automotive aftersales market with its virtual technician platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240807187434/en/
This fresh injection of capital will fuel DC Connected Car's international expansion and development of advanced diagnostic tools for roadside assistance, warranty, and repair. (Graphic: Business Wire)
DC Connected Car's virtual technician platform addresses the shortage of skilled labor in the industry, and their remote diagnostics and advanced AI set new sector benchmarks. Unlike conventional diagnostics, AI-driven solutions deliver automated, intelligent insights into vehicle health and performance, providing real-time problem-solution recommendations. This approach minimizes the need for physical inspections/repairs, but also integrates into customers' lives by offering remote support. By combining AI with remote diagnostics, DC Connected Car redefines vehicle maintenance and customer convenience, solidifying its position as a standout player in the space, highlighted by its partnerships with Major OEMs.
"AI has the potential to revolutionize various automotive areas that Borusan operates in, such as aftersales, fleets, and used car business," said Timo Kilp, Head of Borusan Ventures. "We believe DC Connected Car's AI-driven digital technician holds significant promise to accelerate the diagnosis and repair of vehicle issues, further enhancing our customer service."
Not only disruptive in the automotive repair sector, DC Connected Car is driving innovations in the insurance industry too. Their partnership with Real Garant Versicherung AG marks a new era of digitalization, sustainable mobility, and future-orientated service design.
"With the cooperation with DC Connected Car GmbH, we expect to significantly contribute to environmentally friendly mobility solutions and to drive forward digitalization in the automotive sector by providing digital solutions for warranty and service products,” explains Suzana Janny, Head of Market Proposition at Real Garant Versicherung AG.
This fresh injection of capital will fuel DC Connected Car's international expansion and development of advanced diagnostic tools for roadside assistance, warranty, and repair. The company has seamlessly integrated and digitized expertise across various automotive departments, breaking down silos and enhancing efficiency.
About DC Connected Car GmbH
Founded in 2020 in Leibi, Germany, DC Connected Car offers an all-in-one solution that represents the virtual vehicle technician of the future. This platform addresses the complexities of modern vehicle generations and labor shortage by enabling automated and intelligent diagnostic and repair processes.
"What excites us most about DC Connected Car is the wide range of possible applications for their virtual assistant in the mobility ecosystem. Insurers especially have a high interest in elevating their customer experience by digitizing roadside assistance services. In addition, the team has already impressively demonstrated that it has been able to win well-known B2B customers and OEMs as partners," said Tizian Hoppen of VENPACE.
The team behind DC Connected Car includes experts with deep industry knowledge and experience. Dennis Christ, an expert in automotive technology and a certified appraiser, provides precise and reliable diagnostic procedures. Ralf Schollenberger leverages his extensive network and expertise in insurance and the aftermarket to forge strategic partnerships. Willian Servigna, specializing in AI and software development, ensures that solutions remain at the forefront of technology.
About VENPACE - VENPACE is a leading investor from the insurance space, guiding startups with unique expertise to sustainably scale innovative solutions. Together with partners throughout the DACH region, they tackle the insurance industry’s challenges head-on, developing and establishing innovative business models.
About BORUSAN Ventures - Borusan Ventures is the corporate venture capital arm of Borusan Group, a prominent industrial group in the U.S., Europe and CIS region. Headquartered in Silicon Valley, Borusan Ventures invests in early-stage startups in the U.S. and Europe, focusing on mobility, supply chain/logistics, energy/climate, enterprise, and industrial sectors.
About ATLAS Ventures - Atlas Ventures is a UK-based industrial tech fund focussed on investing in seed and late seed stage opportunities in Developed European markets, with a primary focus on innovative B2B solutions targeting industrial manufacturing, energy and climate, mobility, supply chain and logistics sectors.
For more information, visit https://www.dc-connected.de/en.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240807187434/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aesyra Demonstrates Significant Sleep Bruxism Reduction in Clinical Study26.1.2026 09:00:00 CET | Press release
Aesyra SA, a Swiss medtech company developing innovative digital therapeutics for dental and sleep-related disorders, today announced the successful completion of its clinical investigation evaluating the efficacy and safety of AesyBite™ Active, an intelligent oral appliance designed to treat and prevent sleep bruxism through biofeedback. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126533019/en/ AesyBite Custom smart nightguard by Aesyra SA. The clinical investigation demonstrated that AesyBite™ Active achieved a statistically significant and clinically meaningful reduction in sleep bruxism activity, exceeding the predefined performance target. Strong and robust clinical outcomes In the study (Identifier: NCT06153810), involving 26 adult patients with confirmed sleep bruxism, activation of the AesyBite Active biofeedback system resulted in a 60.6% reduction in total sleep bruxism duration per hour compared to baseline
Franklin Templeton Aligns Alternative Credit Firms Under BSP Brand26.1.2026 08:58:00 CET | Press release
Benefit Street Partners and Alcentra align under a single, refreshed BSP brand.Move reflects client demand for a specialist, integrated and global credit platform.Franklin Templeton’s alternative credit platform on track to exceed $100bn in 2026.BSP outlines further growth plans including expansion in the Middle East and Asia.New research says 51% of institutional investors will increase credit allocation in 2026.81% of institutions say a specialist focus on credit is the top attribute for performance. Franklin Templeton’s US and European alternative credit businesses, Benefit Street Partners and Alcentra, have now aligned under an updated Benefit Street Partners (BSP) brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260123270080/en/ David Manlowe, CEO of Benefit Street Partners The move is the final step in BSP and Alcentra’s integration – two pioneering alternative credit firms that Franklin Templeton acquired in 2019
Samsung Epis Holdings Reports Fourth Quarter and Fiscal Year 2025 Financial Results26.1.2026 08:00:00 CET | Press release
In its first financial results announcement after the spin-off, Samsung Bioepis recorded FY2025 revenue of KRW 1.672 trillion, highest annual revenue in its 14-year historyExcluding milestone revenue, annual sales revenue grew 28% year-over-year (YoY), recording KRW 1.626 trillion, with 101% YoY growth in operating profit to KRW 330.8 billion Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced financial results for the fourth quarter and fiscal year 2025. “We are very pleased to report strong year-to-date sales growth in our first financial results following the spin-off. Our organic growth has been driven by solid performance across our biosimilars portfolio," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We are continuing to make meaningful progress in our regulatory and commercial milestones with our existing biosimilars portfolio, while strategically
Syngenta and Statkraft Sign Five-Year Virtual Power Purchase Agreement26.1.2026 08:00:00 CET | Press release
Virtual wind PPA with guarantees of origin to decarbonize Syngenta's plants in Europe Important element in carbon reduction journey for Syngenta AG Syngenta, one of the world’s biggest agricultural innovation companies, and Statkraft, a leading provider of innovative green energy solutions in Europe, have signed a virtual power purchase agreement (vPPA) covering Syngenta’s CP & Seeds operations for a period of five years. The volume amounts to 125 GWh per year and a total of 625 GWh of green electricity by the end of the contract in 2030. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260125701845/en/ Syngenta and Statkraft sign five-year virtual power purchase agreement With the vPPA, Statkraft is supporting Syngenta in advancing its sustainability strategy through the purchase of renewable energy. "This is Syngenta's first vPPA, marking a pivotal step in our decarbonization strategy," said Rachel Stenson Bugnon, Global Hea
Merz Therapeutics Submits Application to the European Medicines Agency for New Indication of XEOMIN® in Pediatric Spasticity26.1.2026 08:00:00 CET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that it has completed the regulatory submission for XEOMIN® (incobotulinumtoxinA) for the treatment of spasticity of the lower and upper limb in children and adolescents aged 2–17 years in the European Union (EU) and European Economic Area (EEA). If approved, the indication would expand access to an established botulinum neurotoxin therapy for some of the youngest and most vulnerable patients across Europe. Spasticity is a common and often debilitating condition in children and adolescents with certain neurological conditions, leading to increased muscle tone that can significantly limit movement, function and independence. One of the most common underlying causes of spasticity in children is cerebral palsy (CP), the most frequent motor disability in childhood, with spastic forms accounting for approximately 80% of all cases. In more severe cases, spasticity associated with CP can also affect spe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom